{
    "url_original": "https://www.wsj.com/articles/the-baby-formula-fiasco-is-a-lesson-in-planning-and-incentives-11654012877?mod=opinion_major_pos17",
    "url": "the-baby-formula-fiasco-is-a-lesson-in-planning-and-incentives-11654012877",
    "title": "The Baby Formula Fiasco Is a Lesson in Planning and Incentives",
    "sub_head": "The risk-reward distortion exists at every level of government.",
    "category_1": "Opinion",
    "category_2": "Letters",
    "image_1_url": "https://images.wsj.net/im-554372?width=860&height=573",
    "image_1": "im-554372.jpg",
    "time": "2022-05-31 12:01:00",
    "body": "Regarding Holman Jenkins, Jr.’s “One Bad Choice and a Baby Formula Crisis” (Business World, May 21): Competent management at the FDA would have had a contingency plan in place to address such situations as arose at  Abbott Laboratories .  Preauthorized foreign suppliers should have been called into play immediately, avoiding the delays of a reactive approval process. It’s common sense.<br />Roger Baier"
}